Pharma Insight ApS: Financial statements 2023
CVR: 40637117
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Pharma Insight ApS (CVR 40637117) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -17,122 and a net result of DKK -18,857 compared with DKK -26,615 the year before. Equity in the 2023 report amounted to DKK 27,345. The solvency ratio was 57.8%.
- Gross Profit
- DKK -17,122
- Profit/Loss
- DKK -18,857
- Equity
- DKK 27,345
- Total Assets
- DKK 47,313
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -17 t. | -19 t. | 27 t. | 0 |
| 2022 | - | -27 t. | -27 t. | 146 t. | 1 |
| 2021 | - | 725 t. | 48 t. | 273 t. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Pharma Insight ApS has published its annual report for 2022. Gross profit came to DKK -27,014, and the net result was DKK -26,615.
About Pharma Insight ApS
Pharma Insight ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Marianne Kock and Peter Kock. The company is owned by Peter Kock Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 342,207 and a net result of DKK 265,159 compared with DKK 117,750 the year before. Equity in the 2025 report amounted to DKK 340,254.